Global Next-Generation Sequencing (NGS) Market Research Report (2025–2036)
Western Market Research predicts that the Global Next-Generation Sequencing (NGS) Market was valued at USD 11.52 Billion in 2025 and is projected to reach USD 42.84 Billion by the year 2036, growing at a CAGR of 12.6% globally during the forecast period.
1. Global Next-Generation Sequencing Market Overview
The Next-Generation Sequencing (NGS) market is currently undergoing a "clinical revolution." Once restricted to high-end academic research, NGS has transitioned into a standard-of-care tool for oncology, prenatal testing, and rare disease diagnosis. The industry is moving toward the "democratization of genomics," driven by the $100 genome milestone, which has made deep genetic insights accessible to mid-sized hospitals and emerging economies.
This research analyzes the technical progress in high-throughput platforms and the integration of artificial intelligence in bioinformatics. By evaluating historical data from 2020–2024, the report provides a strategic management roadmap through 2036, focusing on the shift from short-read to long-read sequencing and the rise of decentralized testing.
2. Impact of COVID-19 on the NGS Market
The COVID-19 pandemic served as a massive structural catalyst for the NGS market. In 2020, NGS became the primary tool for viral surveillance, variant tracking, and understanding host-pathogen interactions. This led to a global surge in laboratory infrastructure investment. Post-pandemic, these facilities have been repurposed for oncology and infectious disease monitoring, creating a permanent high-demand floor for NGS consumables and reagents.
3. Market Segmentation
By Technology:
-
Sequencing by Synthesis (SBS): The dominant segment, led by Illumina’s chemistry.
-
Ion Semiconductor Sequencing: Known for speed and lower capital costs.
-
Nanopore Sequencing: Rapidly growing segment focused on real-time, portable, long-read sequencing.
-
Single-Molecule Real-Time (SMRT) Sequencing: Preferred for complex genomic regions and structural variations.
By Product & Service (New Segment):
-
Consumables: The largest revenue generator, driven by recurring sales of kits and reagents.
-
Platforms (Sequencers): High-throughput, mid-throughput, and benchtop units.
-
Bioinformatics & Software: Tools for secondary and tertiary data analysis.
By Application:
-
Oncology: Liquid biopsies, companion diagnostics, and personalized immunotherapy.
-
Reproductive Health: Non-Invasive Prenatal Testing (NIPT) and Pre-implantation Genetic Screening (PGS).
-
Infectious Diseases (New): Rapid pathogen identification and antimicrobial resistance (AMR) tracking.
-
Life Science Research: Fundamental genomics, transcriptomics, and epigenetics.
-
Agrigenomics & Forensics: Seed purity testing and high-resolution forensic profiling.
By End-User:
-
Academic & Government Institutes
-
Pharmaceutical & Biotechnology Companies
-
Hospitals & Diagnostic Centers
-
Contract Research Organizations (CROs)
4. Top Key Players Covered
-
Illumina, Inc. (USA)
-
Thermo Fisher Scientific Inc. (USA) (Includes Applied Biosystems/Life Technologies)
-
Pacific Biosciences (PacBio) (USA)
-
Oxford Nanopore Technologies (UK)
-
BGI Group / MGI Tech (China)
-
Agilent Technologies, Inc. (USA)
-
Qiagen N.V. (Germany/Netherlands)
-
F. Hoffmann-La Roche Ltd (Switzerland)
-
PerkinElmer, Inc. (USA)
-
10x Genomics (USA)
-
Eurofins Scientific (Luxembourg)
5. Regional Analysis
-
North America: Holds the largest share (~45%) due to early clinical adoption of NGS, favorable reimbursement for oncology, and the headquarters of major industry players.
-
Europe: A major hub for R&D, driven by government-funded genomic projects (e.g., Genomic Medicine Service in the UK).
-
Asia-Pacific: The fastest-growing region. Large population pools in China and India, coupled with massive investments in healthcare infrastructure and local platform manufacturing (MGI Tech), are primary drivers.
-
South America & MEA: Emerging markets focusing on using NGS for infectious disease control and agricultural improvement.
6. Porter’s Five Forces Analysis
-
Threat of New Entrants (Low): High barriers due to massive R&D costs and an intensive patent landscape.
-
Bargaining Power of Buyers (Medium-High): Large hospital networks and pharma companies have significant leverage, though they are often "locked-in" to a specific manufacturer’s consumable ecosystem.
-
Bargaining Power of Suppliers (Low): Raw materials for NGS kits are standardized, though specialized enzyme providers have some niche power.
-
Threat of Substitutes (Low): Sanger sequencing and microarrays coexist but cannot match the depth and scale of NGS.
-
Competitive Rivalry (High): Intense competition between short-read leaders (Illumina) and long-read innovators (Oxford Nanopore/PacBio).
7. SWOT Analysis
-
Strengths: Unmatched precision; high-throughput capabilities; decreasing cost-per-gigabase.
-
Weaknesses: High complexity of data analysis; substantial initial capital investment for sequencers.
-
Opportunities: Expansion of NIPT in emerging markets; use of NGS in routine infectious disease diagnostics (Point-of-Care).
-
Threats: Data privacy and ethical concerns; fluctuating government research budgets.
8. Trend Analysis
-
The Rise of Long-Read Sequencing: Growing preference for Nanopore/SMRT technologies to resolve complex structural variations.
-
Multi-Omics Integration: Combining NGS data with proteomics and metabolomics for a 360-degree view of patient health.
-
Cloud-Based Bioinformatics: Moving data storage and analysis to the cloud to manage the massive "big data" output of NGS runs.
9. Drivers & Challenges
-
Drivers:
-
Rising global prevalence of cancer and chronic diseases.
-
Transition from "General Medicine" to "Precision Medicine."
-
Technological breakthroughs in single-cell sequencing.
-
-
Challenges:
-
The "Bioinformatics Bottleneck": Analyzing data is now more expensive and complex than generating it.
-
Lack of standardized regulatory frameworks for NGS-based clinical tests across different countries.
-
10. Value Chain Analysis
-
Upstream: R&D, patent acquisition, and enzyme/chemical manufacturing.
-
Midstream: Assembly of sequencers and formulation of library preparation kits.
-
Downstream: Clinical testing services (Hospitals/Labs) and data interpretation.
-
End-User: Physicians and patients receiving personalized treatment plans.
11. Quick Recommendations for Stakeholders
-
For Manufacturers: Focus on "Sample-to-Insight" solutions—integrated platforms that automate the entire workflow from sample prep to the final clinical report.
-
For Diagnostic Labs: Invest in bioinformatics expertise rather than just hardware; data interpretation is the primary value-add in the modern market.
-
For Investors: Target companies specialized in Liquid Biopsy and Early Cancer Detection, as these applications represent the highest volume growth over the next decade.
-
For Policy Makers: Standardize genomic data privacy laws to facilitate cross-border research while protecting patient identity.
1. Market Overview of Next-Generation Sequencing
1.1 Next-Generation Sequencing Market Overview
1.1.1 Next-Generation Sequencing Product Scope
1.1.2 Market Status and Outlook
1.2 Next-Generation Sequencing Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Next-Generation Sequencing Historic Market Size by Regions
1.4 Next-Generation Sequencing Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Next-Generation Sequencing Sales Market by Type
2.1 Global Next-Generation Sequencing Historic Market Size by Type
2.2 Global Next-Generation Sequencing Forecasted Market Size by Type
2.3 Sequencing by Synthesis
2.4 Sequencing by Ligation
3. Covid-19 Impact Next-Generation Sequencing Sales Market by Application
3.1 Global Next-Generation Sequencing Historic Market Size by Application
3.2 Global Next-Generation Sequencing Forecasted Market Size by Application
3.3 Oncology
3.4 Hereditary Disease Detection
3.5 Life Science
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Next-Generation Sequencing Production Capacity Market Share by Manufacturers
4.2 Global Next-Generation Sequencing Revenue Market Share by Manufacturers
4.3 Global Next-Generation Sequencing Average Price by Manufacturers
5. Company Profiles and Key Figures in Next-Generation Sequencing Business
5.1 Illumina
5.1.1 Illumina Company Profile
5.1.2 Illumina Next-Generation Sequencing Product Specification
5.1.3 Illumina Next-Generation Sequencing Production Capacity, Revenue, Price and Gross Margin
5.2 Applied Biosystems (ABI)
5.2.1 Applied Biosystems (ABI) Company Profile
5.2.2 Applied Biosystems (ABI) Next-Generation Sequencing Product Specification
5.2.3 Applied Biosystems (ABI) Next-Generation Sequencing Production Capacity, Revenue, Price and Gross Margin
5.3 Roche (454)
5.3.1 Roche (454) Company Profile
5.3.2 Roche (454) Next-Generation Sequencing Product Specification
5.3.3 Roche (454) Next-Generation Sequencing Production Capacity, Revenue, Price and Gross Margin
5.4 Helicos
5.4.1 Helicos Company Profile
5.4.2 Helicos Next-Generation Sequencing Product Specification
5.4.3 Helicos Next-Generation Sequencing Production Capacity, Revenue, Price and Gross Margin
5.5 LifeTechnologies
5.5.1 LifeTechnologies Company Profile
5.5.2 LifeTechnologies Next-Generation Sequencing Product Specification
5.5.3 LifeTechnologies Next-Generation Sequencing Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Next-Generation Sequencing Market Size
6.2 North America Next-Generation Sequencing Key Players in North America
6.3 North America Next-Generation Sequencing Market Size by Type
6.4 North America Next-Generation Sequencing Market Size by Application
7. East Asia
7.1 East Asia Next-Generation Sequencing Market Size
7.2 East Asia Next-Generation Sequencing Key Players in North America
7.3 East Asia Next-Generation Sequencing Market Size by Type
7.4 East Asia Next-Generation Sequencing Market Size by Application
8. Europe
8.1 Europe Next-Generation Sequencing Market Size
8.2 Europe Next-Generation Sequencing Key Players in North America
8.3 Europe Next-Generation Sequencing Market Size by Type
8.4 Europe Next-Generation Sequencing Market Size by Application
9. South Asia
9.1 South Asia Next-Generation Sequencing Market Size
9.2 South Asia Next-Generation Sequencing Key Players in North America
9.3 South Asia Next-Generation Sequencing Market Size by Type
9.4 South Asia Next-Generation Sequencing Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Next-Generation Sequencing Market Size
10.2 Southeast Asia Next-Generation Sequencing Key Players in North America
10.3 Southeast Asia Next-Generation Sequencing Market Size by Type
10.4 Southeast Asia Next-Generation Sequencing Market Size by Application
11. Middle East
11.1 Middle East Next-Generation Sequencing Market Size
11.2 Middle East Next-Generation Sequencing Key Players in North America
11.3 Middle East Next-Generation Sequencing Market Size by Type
11.4 Middle East Next-Generation Sequencing Market Size by Application
12. Africa
12.1 Africa Next-Generation Sequencing Market Size
12.2 Africa Next-Generation Sequencing Key Players in North America
12.3 Africa Next-Generation Sequencing Market Size by Type
12.4 Africa Next-Generation Sequencing Market Size by Application
13. Oceania
13.1 Oceania Next-Generation Sequencing Market Size
13.2 Oceania Next-Generation Sequencing Key Players in North America
13.3 Oceania Next-Generation Sequencing Market Size by Type
13.4 Oceania Next-Generation Sequencing Market Size by Application
14. South America
14.1 South America Next-Generation Sequencing Market Size
14.2 South America Next-Generation Sequencing Key Players in North America
14.3 South America Next-Generation Sequencing Market Size by Type
14.4 South America Next-Generation Sequencing Market Size by Application
15. Rest of the World
15.1 Rest of the World Next-Generation Sequencing Market Size
15.2 Rest of the World Next-Generation Sequencing Key Players in North America
15.3 Rest of the World Next-Generation Sequencing Market Size by Type
15.4 Rest of the World Next-Generation Sequencing Market Size by Application
16 Next-Generation Sequencing Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Market Segmentation
By Technology:
-
Sequencing by Synthesis (SBS): The dominant segment, led by Illumina’s chemistry.
-
Ion Semiconductor Sequencing: Known for speed and lower capital costs.
-
Nanopore Sequencing: Rapidly growing segment focused on real-time, portable, long-read sequencing.
-
Single-Molecule Real-Time (SMRT) Sequencing: Preferred for complex genomic regions and structural variations.
By Product & Service (New Segment):
-
Consumables: The largest revenue generator, driven by recurring sales of kits and reagents.
-
Platforms (Sequencers): High-throughput, mid-throughput, and benchtop units.
-
Bioinformatics & Software: Tools for secondary and tertiary data analysis.
By Application:
-
Oncology: Liquid biopsies, companion diagnostics, and personalized immunotherapy.
-
Reproductive Health: Non-Invasive Prenatal Testing (NIPT) and Pre-implantation Genetic Screening (PGS).
-
Infectious Diseases (New): Rapid pathogen identification and antimicrobial resistance (AMR) tracking.
-
Life Science Research: Fundamental genomics, transcriptomics, and epigenetics.
-
Agrigenomics & Forensics: Seed purity testing and high-resolution forensic profiling.
By End-User:
-
Academic & Government Institutes
-
Pharmaceutical & Biotechnology Companies
-
Hospitals & Diagnostic Centers
-
Contract Research Organizations (CROs)
4. Top Key Players Covered
-
Illumina, Inc. (USA)
-
Thermo Fisher Scientific Inc. (USA) (Includes Applied Biosystems/Life Technologies)
-
Pacific Biosciences (PacBio) (USA)
-
Oxford Nanopore Technologies (UK)
-
BGI Group / MGI Tech (China)
-
Agilent Technologies, Inc. (USA)
-
Qiagen N.V. (Germany/Netherlands)
